Biomarker Panel for Arteriovascular Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting arteriovascular events in asymptomatic individuals are inadequate, as existing biomarker-based approaches suffer from low specificity, high false positives, and limited transferability between populations, failing to accurately identify individuals at risk who do not exhibit traditional risk factors.
Innovation Solution
A panel of biomarkers including ADIPOQ, Age, SHBG, ADIPOQ + Age + LEP, ADIPOQ + Age + POMC + SHBG is used to assess the risk of arteriovascular events in subjects, combining traditional and novel biomarkers to improve predictive accuracy and detect asymptomatic individuals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional risk factor assessment methods are used to predict arteriovascular events, then sensitivity to individuals with multiple risk factors is improved, but specificity deteriorates resulting in high false positives
Solution Approach 1:
The patent segments the risk assessment into multiple independent biomarker measurements (ADIPOQ, LEP, POMC, SHBG) rather than using a single composite score. Each biomarker is measured and evaluated separately, allowing for more precise identification of true risk while reducing false positives from traditional methods that conflate multiple risk factors into one assessment.
Solution Approach 2:
The patent changes the parameters being measured from traditional risk factors (cholesterol, blood pressure) to novel biomarkers (ADIPOQ, LEP, POMC, SHBG) that provide different information about arteriovascular risk. This parameter change enables detection of risk in asymptomatic individuals without traditional risk factors, improving both sensitivity and specificity simultaneously.
2Reliability
If existing biomarker-based approaches are applied to asymptomatic individuals, then risk prediction capability is improved, but transferability between populations deteriorates
Solution Approach 1:
The patent develops a universal biomarker panel that functions across diverse populations without requiring population-specific calibration. The combination of ADIPOQ, LEP, POMC, and SHBG measurements provides a multi-functional assessment tool that maintains consistent predictive performance whether applied to populations with or without traditional risk factors, enabling broad transferability while preserving risk prediction capability.
3Measurement precision
If traditional risk factor screening is used, then identification of high-risk individuals with multiple factors is improved, but detection of asymptomatic individuals without traditional risk factors deteriorates
Solution Approach 1:
The patent measures novel biomarkers (ADIPOQ, LEP, POMC, SHBG) that capture different aspects of arteriovascular risk not reflected in traditional risk factors. These parameter changes enable detection of risk mechanisms in asymptomatic individuals without traditional risk factors, while maintaining accurate identification of high-risk individuals through the same biomarker panel.
Data Source
Figure 1
Figure 2
Figure 2A
AI summary
Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluatinig the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.